TAG and COVID-19 Prevention Network Fall 2020 Webinars
TAG is hosting a series of webinars on COVID-19 biomedical prevention research in collaboration with the CoVPN. Information and videos from the first two events may be found on this page.
Investment in HIV Research Profoundly Benefits the COVID-19 Response
This policy brief discusses how investment in HIV research has profoundly benefitted the COVID-19 response, and advocates that continued financial support for HIV science can both ensure progress on COVID-19 and avoid losing ground—and lives—in the fight to end the HIV epidemic.
COVID-19 and Impacted Communities: A Media Communications Guide
This easy-to-use guide is designed to provide journalists and communication professionals the tools needed to ensure accurate reporting and curb any related stigma associated with the novel coronavirus SARS-COV-2, also known and reported as COVID-19. We invite you to use this to inform your own writing and to share it with colleagues and cohorts that work in media and communications.
The Future of Biomedical HIV Prevention Trials: Researcher Viewpoints and Community Survey
This report aims to make more accessible to community advocates discussions around ethical conduct of biomedical prevention trials in the era of PrEP. In early 2019, TAG, along with Black AIDS Institute and the HIV Vaccine Trials Network developed an…
Protestors Demand Cepheid Halve the Price of GeneXpert TB Tests to US$5
The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.
Public Investments in TB Medicine Bedaquiline Far Exceed Those of Developer Johnson & Johnson
Presented at the 50th Union World Conference on Lung Health, an analysis by Treatment Action Group (TAG) finds that total public expenditures on the development of bedaquiline –– an important medicine for drug-resistant tuberculosis (DR-TB) –– far exceed those of the originator company, Johnson & Johnson.
ACT NOW: END AIDS Coalition to Offer Community Leadership Grants
October 21, 2019 – The ACT NOW: END AIDS (ANEA) coalition is seeking proposals for a new small grants program that aims to significantly increase local and state community leadership as part of the new federal Ending the HIV Epidemic…
Forging A Path to HCV Elimination: Simpler Tests and Affordable Generics
In July 2017, 37 treatment activists from 17 countries—including 14 low- and middle-income countries (LMICs)—met with representatives from three generics and three diagnostics companies. This Hepatitis C World Community Advisory Board meeting was an opportunity for activists to present demands…